Adastra Holdings Past Earnings Performance
Past criteria checks 0/6
Adastra Holdings has been growing earnings at an average annual rate of 5.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 60.6% per year.
Key information
5.4%
Earnings growth rate
14.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 60.6% |
| Return on equity | -25.0% |
| Net Margin | -14.8% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Adastra Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 23 | -3 | 9 | 0 |
| 31 Mar 24 | 23 | -5 | 10 | 0 |
| 31 Dec 23 | 22 | -4 | 9 | 0 |
| 30 Sep 23 | 21 | -5 | 9 | 0 |
| 30 Jun 23 | 21 | -5 | 8 | 0 |
| 31 Mar 23 | 17 | -4 | 7 | 0 |
| 31 Dec 22 | 13 | -4 | 6 | 0 |
| 30 Sep 22 | 11 | -3 | 7 | 0 |
| 30 Jun 22 | 9 | -3 | 6 | 0 |
| 31 Mar 22 | 7 | -3 | 5 | 0 |
| 31 Dec 21 | 6 | -3 | 4 | 0 |
| 30 Sep 21 | 5 | -1 | 2 | 0 |
| 30 Jun 21 | 4 | -5 | 5 | 0 |
| 31 Mar 21 | 3 | -5 | 5 | 0 |
| 31 Dec 20 | 2 | -8 | 8 | 0 |
| 30 Sep 20 | 1 | -11 | 8 | 0 |
| 30 Jun 20 | 0 | -7 | 5 | 0 |
| 31 Mar 20 | 0 | -7 | 4 | 0 |
| 31 Dec 19 | 0 | -4 | 2 | 0 |
| 31 Oct 19 | 0 | -2 | 1 | 0 |
| 31 Jul 19 | 0 | -1 | 1 | 0 |
Quality Earnings: D2E0 is currently unprofitable.
Growing Profit Margin: D2E0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: D2E0 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.4% per year.
Accelerating Growth: Unable to compare D2E0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: D2E0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: D2E0 has a negative Return on Equity (-24.99%), as it is currently unprofitable.